The report focuses on the antidiabetic, also termed insulin-like, effect of various vanadium and chromium derivatives, proposed mechanisms of their activity, their use in in vivo and in vitro studies, as well as in diabetic patients, their toxicity and effectiveness in controlling clinical signs of diabetes. Studies indicate that compounds of vanadium and chromium is necessary for regulation of carbohydrate and lipid metabolism mainly due to increasing the number of insulin receptors and its activation by phosphorylation. Some authors believe that compounds of chromium(III) deficiency can lead to glucose intolerance and symptoms of type 2 diabetes. However, due to methodological limitations of many clinical studies, the statements of major diabetes associations concerning recommendation of various vanadium and chromium derivatives supplementation in individuals with diabetes and obesity still remains negative. Additional studies are urgently needed to elucidate the mechanism of action of chromium and vanadium compounds and its role in the prevention and control of diabetes.
JavaScript jest wyłączony w Twojej przeglądarce internetowej. Włącz go, a następnie odśwież stronę, aby móc w pełni z niej korzystać.